

December 9, 2014

Streamline Health® Reports Third Quarter 2014 Revenues Of \$6.8 Million; Recurring Revenues Up 11% Over Q3 2013

Company Sets New Record for Contract Bookings of \$21.3 Million in Q3

ATLANTA, Dec. 9, 2014 /PRNewswire/ --Â <u>Streamline Health Solutions, Inc.</u> (NASDAQ: STRM), a leading provider of transformational data-driven solutions to help healthcare providers reduce exposure to risk, enhance clinical, financial, and operational performance, and improve patient care, today announced financial results for the third quarter of 2014, which ended October 31, 2014.



Revenues for the three-month period ended October 31, 2014, increased approximately 2% to \$6.8 million versus \$6.7 million in the comparable period of fiscal 2013. Recurring revenues increased 11% in the third quarter over the same period a year earlier and are up 13% YTD over the comparable first nine months of fiscal 2013.

"As previously announced, I'm pleased with the progress we are making in transitioning our Company to a recurring revenue model," stated Robert E. Watson, President and CEO, Streamline Health Solutions, Inc. "For the first nine months of this fiscal year, 89% of our total revenues are recurring, up from 76% for the first nine months of last year. Additionally, we established a new record amount of contract bookings in a single quarter of \$21.3 million, consisting entirely of recurring license revenues and professional services. I have championed a strategy from day one to always try to sell our clients a SaaS-based or recurring revenue based contract versus a perpetual license and it is gratifying to see this kind of recurring revenue and new contract bookings performance."

"With such a successful quarter of new bookings, our committed, unimplemented quarterly recurring revenues continue to build, now standing at approximately \$1.3 million up from \$660,000 at the end of the previous quarter. That's more than \$5 million in annual revenues that are unrecognized. Going forward we are focused on implementing various strategies that will help us convert this revenue in a more timely manner."

Highlights for the third quarter ended October 31, 2014 included:

- Revenues for the third quarter 2014 was \$6.8 million;
- Adjusted EBITDA for the third quarter 2014 was \$(278) thousand;
- Recorded net loss of \$2.3 million for the three-month period ended October 31, 2014;
- Maintenance and support revenues for the quarter increased \$0.5 million over the same period one year ago;
- New sales bookings for the quarter were \$21.3 million
- Backlog at the end of the quarter was \$75.9 million.

Conference Call Information

The Company will conduct a conference call to review the results on Tuesday, December 9, 2014 at 5:00 PM EST. Interested parties can access the call by dialing 888-505-4369 and then entering Conference ID 3681688 Â A live webcast will also be available; <u>click here</u> to register.

A replay of the conference call will be available from Tuesday, December 9, 2014 at 7:00 PM EST to Sunday, December 14, 2014 at 7:00 PM EST by dialing 888-203-1112 and entering passcode 3681688.

*Non-GAAP Financial Measures

Streamline Health reports its financial results in accordance with U.S. generally accepted accounting principles ("GAAP"). Streamline Health's management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline Health's management believes that this measure provides useful supplemental information regarding the performance of Streamline Health's business operations.

Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees . A table illustrating this measure is included in this press release.

About Streamline Health

Streamline Health Solutions, Inc. (NASDAQ: STRM) is a healthcare industry leader in capturing, aggregating, and translating enterprise data into knowledge -- actionable insights that reduce exposure to risk, enhance operational performance, and improve patient care. Through our Looking Glass[™] Platform we provide clients with meaningful, intelligent SaaS-based solutions from patient engagement to reimbursement. We share a common calling and commitment to advance the quality of life and the quality of healthcare -- for society, our industry, our clients, the communities they serve, and the individual patient. For more information, please visit our website at www.streamlinehealth.net.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company's estimates of future revenue, backlog, renewal sales and related expectations and assumptions. Â These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development, key strategic alliances with vendors and channel partners that resell the Company's solutions, the ability of the Company to control costs, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, and the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Company Contact:

Randy Salisbury SVP, Chief Marketing Officer (404) 229-4242 randy.salisbury@streamlinehealth.net

Â

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

		onth Oct 3 ^r	is Ended 1,		ths Ended 31,	
	2014	_	2013	2014	_	2013
Revenues:						
Systems sales \$	345,919	\$	347,532	\$ 999,209	\$	2,905,846
Professional services	447,939		966,962	1,731,888		2,925,553
Maintenance and support	4,062,442		3,523,551	12,411,419,		10,524,595
Software as a service	1,980,343		1,893,489	5,887,368		5,622,237
Total revenues	6,836,643	-	6,731,534	21,029,884		21,978,231

Operating expenses:					
Cost of systems sales	835,398		611,887	2,505,190	1,911,609
Cost of services	681,350		1,262,559	2,446,466	3,503,765
Cost of maintenance and support	756,469		739,887	2,553,180	2,519,952
Cost of software as a service	770,347		520,062	2,113,390	1,613,217
Selling, general and administrative	4,230,347		3,373,230	12,925,597	10,362,246
Research and development	2,275,410	-	1,370,178	6,850,973	3,627,336
Total operating expenses	9,549,321	-	7,877,803	29,394,796	23,538,125
Operating loss	(2,712,678)		(1,146,269)	(8,364,912)	(1,559,894)
Other expense (income):					
Interest expense	(180,583)		(580,390)	(523,599)	(1,734,763)
Loss on early extinguishment of debt	(114,522)		-	(114,522)	-
Miscellaneous income (expenses)	752,219	-	(4,510,439)	1,803,509	(6,316,867)
Loss before income taxes	(2,255,564)		(6,237,098)	(7,199,524)	(9,611,524)
Income tax benefit (expense)		-	4,680	(2,290)	(158,944)
Net loss	\$ (2,255,564)	\$	(6,232,418)	\$ (7,201,814)	\$ (9,770,468)
Less: deemed dividends on Series A Preferred Shares	(269,152)	-	(374,162)	(751,501)	(731,309)
Net loss attributable to common shareholders	\$ (2,524,716)	\$	(6,606,580)	\$ (7,953,315)	\$ (10,501,777)
Basic net loss per common share	\$ (0.14)	\$	(0.50)	\$ (0.44)	\$ (0.82)
Number of shares used in basic per common share computation	18,309,677		13,257,943	18,210,034	12,884,711
Diluted net loss per common share	\$ (0.14)	\$	(0.50)	\$ (0.44)	\$ (0.82)
Number of shares used in diluted per common share computation	18,309,677	-	13,257,943	18,210,034	12,884,711

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

Assets

	October 31, 2014	January 31, 2014
Current assets:		
Cash and cash equivalents \$	5,944,750	\$ 17,924,886
Accounts receivable, net of allowance for doubtful		
accounts of \$477,994 and \$267,264, respectively	5,917,038	7,999,571
Contract receivables	213,652	1,181,606
Prepaid hardware and third party software for		
future delivery	33,473	25,640
Prepaid client maintenance contracts	1,017,261	909,464
Other prepaid assets	1,447,214	1,407,515
Deferred income taxes	95,498	95,498
Other current assets	55,694	144,049
Total current assets	14,724,580	29,688,229
Non-current assets: Property and equipment: Computer equipment Computer software Office furniture, fixtures and equipment Leasehold improvements	4,854,578 2,521,293 687,407 1,227,999	3,769,564 2,239,654 889,080 697,570
	9,291,277	7,595,868
Accumulated depreciation and amortization	(6,012,436)	(6,676,824)
Property and equipment, net	3,278,841	919,044
Contract receivables, less current portion Capitalized software development costs, net of accumulated amortization of \$10,904,467 and	52,263	78,395
\$7,949,352, respectively Intangible assets, net of accumulated amortization Â	10,044,129	10,238,357
of \$2,981,391 and \$1,930,366, respectively Deferred financing, costs net of accumulated	11,797,610	12,175,634
amortization, \$107,271 and \$98,102, respectively	120,760	44,898

A Goodwill	15,889,595	11,933,683
Other	841,432	500,634
Total non-current assets	42,024,630	35,890,645
	\$ 56,749,210	\$ 65,578,874

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

Liabilities and Stockholders' Equity

	October 31, 2014		January 31, 2014
Current liabilities:			
Accounts payable	\$ 2,173,577	\$	1,796,418
Accrued compensation	1,073,771		1,782,599
Accrued other expenses	962,247		554,877
Current portion of long-term debt	1,214,280		1,214,280
Deferred revenues	8,215,846		9,658,232
Current portion of note payable	-		300,000
Current portion of capital lease obligation	795,339	-	105,573
Total current liabilities	14,435,060	-	15,411,979
Non-current liabilities:			
Term loans	5,887,331		6,971,767
Warrants liability	1,791,901		4,117,725
Royalty liability	2,376,564		2,264,000
Swap contract	-		111,086
Note payable	600,000		600,000
Lease incentive liability, less current portion	220,883		74,434
Capital lease obligation	772,804		121,089
Deferred revenues, less current portion	114,433		-
Deferred income tax liability, less current portion	825,677	-	816,079
Total non-current liabilities	12,589,593		15,076,180
Total liabilities	27,024,653	-	30,488,159
Series A 0% Convertible Redeemable Preferred stock, \$.01 par value per share, \$8,849,985 and \$8,849,985 redemption value, 4,000,000 shares authorized, 2,949,995 and 2,949,995 issued and outstanding, net of unamortized preferred stock discount of \$2,498,816 and \$3,250,317, respectively	6,351,169		5,599,668
Stockholders' equity:			
Common stock, \$.01 par value per share, 45,000,000 shares			
authorized, 18,458,745 and 18,175,787 shares issued and			
outstanding, respectively	184,588		181,758
Additional paid in capital	77,953,327		76,983,088
Accumulated deficit	(54,764,527)		(47,562,713)
Accumulated other comprehensive loss		_	(111,086)
Total stockholders' equity	23,373,388	-	29,491,047
	\$ 56,749,210	\$	65,578,874

Â

STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Nine Months Ended Oct 31,					
	2014	_	2013			
Operating activities: Net loss Adjustments to reconcile net loss to net cash (used in) provided by	\$ (7,201,814)	\$	(9,770,468)			
operating activities: Depreciation	670,955		490,043			

Amortization of intangible assets1,051,025946,228 $A Å Å Å$ Å A Amortization of other deferred costs172,804296,942 $A Å Å Å$ Share-based compensation expense1,286,1451,203,919 $A Å Å Å$ Share-based compensation expense1,286,1451,203,919 $A Å Å Å$ A Loss on disposal of fixed assets110,710- $A Å Å Å$ Loss on exit of operating lease234,823- $A Å Å Å$ Deferred tax expense-150,634 $Å Å Å Å$ Deferred tax expense-150,634 $Å Changes in assets and liabilities, net of assets acquired:Accounts and contract receivables3,360,7802,509,842Other assets(314,501)(627,883)Accounts payable410,39587,014Account s payable(2,124,790)(2,683,899)ANet cash (used in) provided by operating activities(2,361,980)Investing activities:(1,047,938)Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)ANet cash used in investing activities(266,212)-Principal repayments on note payable(300,000)-ANet cash (used in) provided by financing activities(11,980,136)Financing activities:(256,212)-Principal repayments on note payable(300,000)-Principal repayments on$	Amortization of capitalized software development costs	2,735,990		2,086,885
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Amortization of intangible assets	1,051,025		946,228
Â Share-based compensation expense 1,286,145 1,203,919 Â Â Â Ó Other valuation adjustments 119,593 4,140,441 Â Â Â Loss on disposal of fixed assets 110,710 - Â Â Â Loss on exit of operating lease 234,823 - Â Â Â Deferred tax expense - 150,634 Â Changes in assets and liabilities, net of assets acquired: - - Accounts and contract receivables 3,360,780 2,509,842 Other assets (314,501) (627,883) Accounts payable 410,395 87,014 Accourd expenses (801,074) (150,206) Deferred revenues (2,124,790) (2,683,899) Â Net cash (used in) provided by operating activities (2,361,980) 762,281 Investing activities: - - - Purchases of property and equipment (1,862,855) (106,392) - Capitalization of software development costs (503,464) (1,047,938) - Payment for acquisition (6,058,225) (3,000,000) - - Financing activities: - - - -	Amortization of other deferred costs	172,804		296,942
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Valuation adjustment for warrants liability	(2,325,824)		2,082,789
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Share-based compensation expense	1,286,145		1,203,919
Loss on exit of operating lease234,823- Provision for accounts receivable252,803- Deferred tax expense-150,634 Changes in assets and liabilities, net of assets acquired:Accounts and contract receivables3,360,7802,509,842Other assets(314,501)(627,883)Accounts payable410,39587,014Accourte expenses(801,074)(150,206)Deferred revenues(2,124,790)(2,683,899) Net cash (used in) provided by operating activities(2,361,980)762,281Investing activities:(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000) Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285 Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Other valuation adjustments	119,593		4,140,441
Provision for accounts receivable252,803 Deferred tax expense150,634 Changes in assets and liabilities, net of assets acquired:3,360,780Accounts and contract receivables3,360,780Question assets(314,501)Accounts payable410,395Accrued expenses(801,074)Question assets(2,124,790)Accrued expenses(2,124,790)Questing activities:(2,361,980)Purchases of property and equipment(1,862,855)Capitalization of software development costs(503,464)Questing activities:(3,000,000)Payment for acquisition(6,058,225)A Net cash used in investing activities(300,000)Financing activities:(300,000)Principal repayments on term loan(910,710)Principal repayments on note payable(300,000)Principal payments on capital lease obligation(165,115)Payment of deferred financing costs(256,212)Proceeds from exercise of stock options and stock purchase plan438,425A Net cash (used in) provided by financing activities(1,193,612)Task, A S, A	Loss on disposal of fixed assets	110,710		-
Deferred tax expense - 150,634 Â Changes in assets and liabilities, net of assets acquired: - 150,634 A Counts and contract receivables 3,360,780 2,509,842 Other assets (314,501) (627,883) Accounts payable 410,395 87,014 Accrued expenses (801,074) (150,206) Deferred revenues (2,124,790) (2,683,899) Â Net cash (used in) provided by operating activities (2,361,980) 762,281 Investing activities: Purchases of property and equipment (1,862,855) (106,392) Capitalization of software development costs (503,464) (1,047,938) Payment for acquisition (6,058,225) (3,000,000) Â Net cash used in investing activities (8,424,544) (4,154,330) Financing activities: Principal repayments on term loan (910,710) (937,501) Principal repayments on term loan (910,710) (937,501) - Principal payments on note payable (300,000) - - Proceeds from exercise of stock options and stock purchase plan 438,425 1,093,285 Â Net cash (used in) provid	Loss on exit of operating lease	234,823		-
Changes in assets and liabilities, net of assets acquired:Accounts and contract receivables3,360,7802,509,842Other assets(314,501)(627,883)Accounts payable410,39587,014Accrued expenses(801,074)(150,206)Deferred revenues(2,124,790)(2,683,899) Net cash (used in) provided by operating activities(2,361,980)762,281Investing activities:Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000) Net cash used in investing activities(8424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on capital lease obligation(165,115)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285 Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Provision for accounts receivable	252,803		-
Accounts and contract receivables3,360,7802,509,842Other assets(314,501)(627,883)Accounts payable410,39587,014Accrued expenses(801,074)(150,206)Deferred revenues(2,124,790)(2,683,899)Å Net cash (used in) provided by operating activities(2,361,980)762,281Investing activities:Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Å Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Å Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Deferred tax expense	-		150,634
Other assets(314,501)(627,883)Accounts payable410,39587,014Accrued expenses(801,074)(150,206)Deferred revenues(2,124,790)(2,683,899)Â Net cash (used in) provided by operating activities(2,361,980)762,281Investing activities:(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Changes in assets and liabilities, net of assets acquired:			
Accounts payable410,39587,014Accrued expenses(801,074)(150,206)Deferred revenues(2,124,790)(2,683,899)Â Net cash (used in) provided by operating activities(2,361,980)762,281Investing activities:(2,361,980)762,281Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:(910,710)(937,501)Principal repayments on term loan(910,710)(937,501)Principal repayments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Accounts and contract receivables	3,360,780		2,509,842
Accrued expenses(801,074)(150,206)Deferred revenues(2,124,790)(2,683,899)Â Net cash (used in) provided by operating activities(2,361,980)762,281Investing activities:Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:910,710)(937,501)Principal repayments on term loan(910,710)(937,501)Principal repayments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Other assets	(314,501)		(627,883)
Deferred revenues(2,124,790)(2,683,899)Â Net cash (used in) provided by operating activities(2,361,980)762,281Investing activities:Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(11,93,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Accounts payable	410,395		87,014
ÂNet cash (used in) provided by operating activities(1,362,855)(106,392)Investing activities:Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)ÂNet cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285ÂNet cash uced in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Accrued expenses	(801,074)		(150,206)
Investing activities:(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:(8,424,544)(4,154,330)Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Deferred revenues	(2,124,790)		(2,683,899)
Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Net cash (used in) provided by operating activities	(2,361,980)		762,281
Purchases of property and equipment(1,862,855)(106,392)Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Investing activities:			
Capitalization of software development costs(503,464)(1,047,938)Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:(910,710)(937,501)Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(11,980,136)(3,236,265)Cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	5	(1 862 855)		(106 392)
Payment for acquisition(6,058,225)(3,000,000)Â Net cash used in investing activities(8,424,544)(4,154,330)Financing activities:Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(11,93,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256		,		()
Net cash used in investing activities(8,424,544)(4,154,330)Financing activities: Principal repayments on term loan Principal repayments on note payable Principal payments on capital lease obligation Principal payments on capital lease obligation Proceeds from exercise of stock options and stock purchase plan Net cash (used in) provided by financing activities(910,710) (937,501) (937,501) (937,501) Net cash (used in) provided by financing activities(165,115) (256,212) (11,93,612)- Net cash (used in) provided by financing activities(1,193,612) (11,980,136) (3,236,265)155,784 (3,236,265)Cash and cash equivalents at beginning of period17,924,886 (17,924,8867,500,256 (155,784)		,		
Financing activities:(910,710)(937,501)Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256				
Principal repayments on term loan(910,710)(937,501)Principal repayments on note payable(300,000)-Principal payments on capital lease obligation(165,115)-Payment of deferred financing costs(256,212)-Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(11,93,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	A net cash used in investing activities	(0,+2+,0++)	•	(4,104,000)
Principal repayments on note payable(300,000)Principal payments on capital lease obligation(165,115)Payment of deferred financing costs(256,212)Proceeds from exercise of stock options and stock purchase plan438,425Â Net cash (used in) provided by financing activities(1,193,612)Decrease in cash and cash equivalents(11,980,136)Cash and cash equivalents at beginning of period17,924,8867,500,256	Financing activities:			
Principal payments on capital lease obligation(165,115)Payment of deferred financing costs(256,212)Proceeds from exercise of stock options and stock purchase plan438,425Â Net cash (used in) provided by financing activities(1,193,612)Decrease in cash and cash equivalents(11,980,136)Cash and cash equivalents at beginning of period17,924,8867,500,256	Principal repayments on term loan	(910,710)		(937,501)
Payment of deferred financing costs(256,212)Proceeds from exercise of stock options and stock purchase plan438,425Â Net cash (used in) provided by financing activities(1,193,612)Decrease in cash and cash equivalents(11,980,136)Cash and cash equivalents at beginning of period17,924,8867,500,256	Principal repayments on note payable	(300,000)		-
Proceeds from exercise of stock options and stock purchase plan438,4251,093,285Â Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Principal payments on capital lease obligation	(165,115)		-
Net cash (used in) provided by financing activities(1,193,612)155,784Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Payment of deferred financing costs	(256,212)		-
Decrease in cash and cash equivalents(11,980,136)(3,236,265)Cash and cash equivalents at beginning of period17,924,8867,500,256	Proceeds from exercise of stock options and stock purchase plan	438,425		1,093,285
Cash and cash equivalents at beginning of period 17,924,886 7,500,256	Net cash (used in) provided by financing activities	(1,193,612)		155,784
	Decrease in cash and cash equivalents	(11,980,136)		(3,236,265)
Cash and cash equivalents at end of period \$ 5,944,750 \$ 4,263,991	Cash and cash equivalents at beginning of period	17,924,886		7,500,256
	Cash and cash equivalents at end of period	\$ 5,944,750	\$	4,263,991

STREAMLINE HEALTH SOLUTIONS, INC. Backlog (Unaudited) Table A

	October 31, 2014	January 31, 2014	October 31, 2013
Streamline Health Software Licenses	\$ 21,103,000	\$ 2,230,000	\$ 2,529,000
Hardware and Third Party Software	126,000	79,000	20,000
Professional Services	8,095,000	7,255,000	7,141,000
Maintenance and Support	21,657,000	25,936,000	28,234,000
Software as a Service	24,928,000	21,073,000	17,087,000
Total	\$ 75,909,000	\$ 56,573,000	\$ 55,011,000

Â

STREAMLINE HEALTH SOLUTIONS, INC. New Bookings (Unaudited) Table B

	Three Mon Oct 31	
	Value	% of Total Bookings
Streamline Health Software licenses	\$ 19,463,000	91.6%
Software as a service	-	0.0%
Maintenance and support	30,000	0.1%
Professional services	1,766,000	8.3%

Reconciliation of Non-GAAP Financial Measures (Unaudited) Table C

This press release contains a non-GAAP financial measure under the rules of the U.S. Securities and Exchange Commission for adjusted EBITDA. This non-GAAP information supplements and is not intended to represent a measure of performance in accordance with disclosures required by U.S. generally accepted accounting principles. Non-GAAP financial measures are used internally to manage the business, such as in establishing an annual operating budget. Non-GAAP financial measures are used by Streamline Health's management in its operating and financial decision-making because management believes these measures reflect ongoing business in a manner that allows meaningful period-to-period comparisons. Accordingly, the Company believes it is useful for investors and others to review both GAAP and non-GAAP measures in order to (a)Å understand and evaluate current operating performance and future prospects in the same manner as management does and (b)Â compare in a consistent manner the Company's current financial results with past financial results. The primary limitations associated with the use of non-GAAP financial measures are that these measures may not be directly comparable to the amounts reported by other companies and they do not include all items of income and expense that affect operations. The Company's management compensates for these limitations by considering the company's financial results and outlook as determined in accordance with GAAP and by providing a detailed reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures in the tables attached to this press release. Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, professional and advisory fees, and internal direct costs incurred to complete transactions.

Â

Reconciliation of net earnings (loss) to non-GAAP adjusted EBITDA (in thousands):

Adjusted EBITDA Reconciliation	Three Months Ended					Nine Months Ended				
		Oct 31, 2014		Oct 31, 2013		Oct 31, 2014		Oct 31, 2013		
Net loss	\$	(2,256)	\$	(6,232)	\$	(7,202)	\$	(9,770)		
Interest expense		181		580		524		1,735		
Income tax expense		-		(5)		2		159		
Depreciation		310		152		671		490		
Amortization of capitalized softwareÂ										
development costs		905		691		2,736		2,087		
Amortization of intangible assets		346		314		1,051		946		
Amortization of other costs		50		23		121		47		
EBITDA		(464)	-	(4,477)		(2,097)		(4,306)		
Share-based compensation expense		421	-	378	-	1,286		1,204		
Loss on disposal of fixed assets		27		-		111		-		
Loss on early extinguishment of debt		115		-		115		-		
Associate severances and other costs Â										
relating to transactions or corporateÂ										
restructuring		255		-		831		383		
Non-cash valuation adjustments to Â										
assets and liabilities		(1,061)		4,514		(2,206)		6,223		
Transaction related professional										
fees, advisory fees and other										
internal direct costs		1		138		176		363		
Non-recurring operating expenses		428		-		1,491		53		
Adjusted EBITDA	\$	(278)	\$	553	\$	(293)	\$	3,920		
Adjusted EBITDA Margin ⁽¹⁾		(4%)	=	8%	-	(1%)		18%		
Adjusted EBITDA per diluted share			-							
Earnings (loss) per share - diluted	\$	(0.14)	\$	(0.50)	\$	(0.44)	\$	(0.82)		
Adjusted EBITDA per adjusted diluted shareÂ ⁽²⁾	\$	(0.02)	\$	0.03	\$	(0.02)	\$	0.22		
Diluted weighted average shares		18,309,677		13,257,943		18,210,034		12,884,711		
C C		10,309,077				10,210,034				
Includable incremental shares — adjusted EBITDA $^{(3)}$		-	-	5,058,763		-		5,130,937		

- (1) Adjusted EBITDA as a percentage of GAAP revenues
- (2) Adjusted EBITDA per adjusted diluted share for the Company's common stock is computed using the more dilutive of the two-class method or the ifconverted method.
- (3) The number of incremental shares that would be dilutive under profit assumption, only applicable under a GAAP net loss. If GAAP profit is earned in the current period, no additional incremental shares are assumed.

Â

Logo - http://photos.prnewswire.com/prnh/20140506/85083

To view the original version on PR Newswire, visit:<u>http://www.prnewswire.com/news-releases/streamline-health-reports-third-quarter-2014-revenues-of-68-million-recurring-revenues-up-11-over-q3-2013-300007181.html</u>

SOURCE Streamline Health Solutions, Inc.

News Provided by Acquire Media